Selvita 주식 가격. 0RKT - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

57.00

매수가

0.00

매도가

0.00

거래량

0.00

0.00 일간 변동폭 0.00

57.00 52주 범위 57.00

market_cap

1.318B

전일 종가

57.00

개장가

최근 거래 시간

(O)

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

0.00

발행 주식

23,120,000

배당수익률

주가수익률

-14.31

주당순이익(EPS)

-3.98

매출

67.99M

순이익

-92.11M

섹터

Chemicals & Chem Preps, Nec

산업

Chemicals & Chem Preps, Nec

웹사이트

ryvu.com

본부

Krakow, Pol

설립됨

Selvita Sa is listed in the Chemicals & Chem Preps sector of the 런던증권거래소 with ticker 0RKT. The last closing price for Selvita was PLN57. Over the last year, Selvita shares have traded in a share price range of PLN 57.00 to PLN 57.00.

Selvita currently has 23,120,000 shares in issue. The market capitalisation of Selvita is PLN1.32 billion. Selvita has a price to earnings ratio (PE ratio) of -14.31.

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 23, 2024...

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 9, 2024...

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit PR Newswire KRAKOW, Poland, Sept. 23, 2024 ONCO Prime is a cutting-edge drug discovery...

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress PR Newswire KRAKOW, Poland, June 14, 2024 RVU120 as a single agent showed...

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting PR Newswire KRAKOW, Poland, March 6, 2024 Updated preclinical data will be...

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS PR Newswire KRAKOW...

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting PR Newswire KRAKOW, Poland, Nov. 2, 2023 Updated data from the Phase I trial of RVU120...

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update PR Newswire KRAKOW, Poland, Sept. 28, 2022 KRAKOW, Poland, Sept. 28, 2022 /PRNewswire/ -- Ryvu...

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress PR Newswire KRAKOW, Poland, June 10, 2022 - Clinically...

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting PR Newswire KRAKOW, Poland, March 8, 2022 KRAKOW, Poland, March 8, 2022 /PRNewswire/ -- Ryvu Therapeutics...

기간	시가	고가	저가
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE

기호	가격	볼륨
BLUBlue Star Capital Plc	0.025p (42.86%)	98.74M
SCGLSealand Capital Galaxy Limited	0.415p (38.33%)	13.62M
SCESurface Transforms Plc	0.34p (30.77%)	108.26M
COBRCobra Resources Plc	1.25p (25.00%)	10.33M
IESInvinity Energy Systems Plc	14.50p (23.40%)	3.28M
UOGUnited Oil & Gas Plc	0.125p (-34.21%)	116.68M
SYSSysgroup Plc	21.50p (-24.56%)	512.48k
KEFIKefi Gold And Copper Plc	0.522p (-19.94%)	326.76M
GENLGenel Energy Plc	72.40p (-17.82%)	1.9M
KZGKazera Global Plc	1.075p (-14.00%)	1.25M
ORCPOracle Power Plc	0.0585p (2.63%)	2.12B
NTVONativo Resources Plc	0.0023p (-8.00%)	575.78M
KEFIKefi Gold And Copper Plc	0.522p (-19.94%)	326.76M
TRPTower Resources Plc	0.03p (1.69%)	165.29M
CLONClontarf Energy Plc	0.0335p (-10.67%)	118.1M

기호

가격

볼륨

ORCPOracle Power Plc

0.0585p

(2.63%)

2.12B

NTVONativo Resources Plc

0.0023p

(-8.00%)

575.78M

KEFIKefi Gold And Copper Plc

0.522p

(-19.94%)

326.76M

TRPTower Resources Plc

0.03p

(1.69%)

165.29M

CLONClontarf Energy Plc

0.0335p

(-10.67%)

118.1M

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Selvita Sa (0RKT)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Selvita Sa 정보

0RKT 최신 뉴스

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	시가	고가	저가
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE

기간	시가	고가	저가
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Selvita Sa (0RKT) 시세

Selvita Sa (0RKT)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Selvita Sa 정보

0RKT 최신 뉴스

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	시가	고가	저가
1	57	57	57	DE
4	57	57	57	DE
12	57	57	57	DE
26	57	57	57	DE
52	57	57	57	DE
156	57	57	57	DE
260	57	57	57	DE